Omics-based Biomarkers for the Early Alzheimer Disease Diagnosis and Reliable Therapeutic Targets Development
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background: Alzheimer’s disease (AD), the most common cause of dementia in adulthood, has great medical, social, and economic impact worldwide. Available treatments result in symptomatic relief, and most of them are indicated from the early stages of the disease. Therefore, there is an increasing body of research developing accurate and early diagnoses, as well as diseasemodifying therapies. Objective: Advancing the knowledge of AD physiopathological mechanisms, improving early diagnosis and developing effective treatments from omics-based biomarkers. Methods: Studies using omics technologies to detect early AD, were reviewed with a particular focus on the metabolites/lipids, micro-RNAs and proteins, which are identified as potential biomarkers in non-invasive samples. Results: This review summarizes recent research on metabolomics/lipidomics, epigenomics and proteomics, applied to early AD detection. Main research lines are the study of metabolites from pathways, such as lipid, amino acid and neurotransmitter metabolisms, cholesterol biosynthesis, and Krebs and urea cycles. In addition, some microRNAs and proteins (microglobulins, interleukins), related to a common network with amyloid precursor protein and tau, have been also identified as potential biomarkers. Nevertheless, the reproducibility of results among studies is not good enough and a standard methodological approach is needed in order to obtain accurate information. Conclusion: The assessment of metabolomic/lipidomic, epigenomic and proteomic changes associated with AD to identify early biomarkers in non-invasive samples from well-defined participants groups will potentially allow the advancement in the early diagnosis and improvement of therapeutic interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Lane, C. A., Hardy, J., & Schott, J. M. (2018) · European Journal of Neurology · doi:10.1111/ene.13439 · Cited by 2,616
Wyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention
Qiu, C., Kivipelto, M., & von Strauss, E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/cqiu · Cited by 1,261 · cited 1×
“In general, the incidence level of AD after 70 years of age reaches 9% of the population [2], involving a significant increase in medical and social costs”
BackgroundClassification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048 · cited 2×
“Therefore, changes in these signaling proteins probably cause a specific phenotype of AD in blood samples [29].”
BackgroundHan, X., Rozen, S., Boyle, S. H., Hellegers, C., Cheng, H., Burke, J. R., Welsh-Bohmer, K. A., Doraiswamy, P. M., & Kaddurah-Daouk, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021643 · Cited by 429 · cited 5×
“Among these, some studies in plasma have identified several pathways affected in AD (biosynthesis and metabolism of amino acids, cholesterol, lipids, neurotransmitters, urea cycle and Krebs cycle) [22], highlighting that lipid dysfunction plays an important role in AD physiopathology [23].”
BackgroundResultInfluentialCheng, L., Doecke, J. D., Sharples, R. A., Villemagne, V. L., Fowler, C. J., Rembach, A., Martins, R. N., Rowe, C. C., Macaulay, S. L., Masters, C. L., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.127 · Cited by 409 · cited 3×
“[68] Deep sequencing: AD (n=23), MCI (n=3), HC (n=23) Validation: AD (n=16) MCI (n=8), HC (n=36) Epigenomics Exosomal miRNA biomarkers (hsa-miR361-5p, hsamiR-30e-5p, hsa-miR-93-5p, hsa-miR-15a-5p, hsa-miR-143-3p, hsamiR-335-5p, hsa-miR-106b-5p, hsa-miR101-3p, hsa-miR-424-5p, hsamiR-106a-5p, hsa-miR-18b-5p, hsa-miR-306…”
BackgroundMethodYu, L., Chibnik, L. B., Srivastava, G. P., Pochet, N., Yang, J., Xu, J., Kozubek, J., Obholzer, N., Leurgans, S. E., Schneider, J. A., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.3049 · Cited by 290
Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology
Sattlecker, M., Kiddle, S. J., Newhouse, S., Proitsi, P., Nelson, S., Williams, S., Johnston, C., Killick, R., Simmons, A., Westman, E., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.09.016 · Cited by 223 · cited 3×
“Most of the AD diagnostic models developed in literature from omic tools were based on proteomic signatures and showed satisfactory accuracy (70-94%) [30, 38, 81, 86-89], as well as high sensitivity and specificity (74-85%) [86, 90, 91].”
BackgroundMethodDuits, F. H., Brinkmalm, G., Teunissen, C. E., Brinkmalm, A., Scheltens, P., Van der Flier, W. M., Zetterberg, H., & Blennow, K. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0335-x · Cited by 137 · cited 1×
“In a recent study in CSF samples from MCI-AD patients high levels of several proteins (Chromogranin A, neurexin3, neuropentraxin1) were found, reflecting early events in the physiopathology of AD [73].”
BackgroundGonzález‐Domínguez, R., García, A., García‐Barrera, T., Barbas, C., & Gómez‐Ariza, J. L. (2014) · ELECTROPHORESIS · doi:10.1002/elps.201400196 · Cited by 119 · cited 3×
“On the other hand, inconsistent results were observed for ceramides [23, 38, 52] and acylcarnitines levels in plasma [33, 34, 38, 39, 51, 53], obtaining not satisfactory conclusions about the energy metabolism involvement in AD; while some diacylglycerols were elevated in MCI and AD [38, 54], constituting potential bi…”
BackgroundResultBiomarkers in Sporadic and Familial Alzheimer’s Disease
Lista, S., O’Bryant, S. E., Blennow, K., Dubois, B., Hugon, J., Zetterberg, H., & Hampel, H. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-143006 · Cited by 106
Sultana, R., Baglioni, M., Cecchetti, R., Cai, J., Klein, J. B., Bastiani, P., Ruggiero, C., Mecocci, P., & Butterfield, D. A. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.08.001 · Cited by 64
Prognostic polypeptide blood plasma biomarkers of Alzheimer's disease progression
Yang, H., Lyutvinskiy, Y., Herukka, S.-K., Soininen, H., Rutishauser, D., & Zubarev, R. A. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132102 · Cited by 52 · cited 6×
“3% for discriminating the dementia with Lewy bodies group from the AD group [69], as well as some polypeptides with 79% of accuracy differentiating between stable MCI and progressive MCI [88].”
BackgroundMethodInfluentialKang, S., Jeong, H., Baek, J.-H., Lee, S.-J., Han, S.-H., Cho, H. J., Kim, H., Hong, H. S., Kim, Y. H., Yi, E. C., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160025 · Cited by 30 · cited 3×
“Moreover, there are few studies validating the potential biomarkers in independent samples [80, 81, 91, 95, 97].”
Background
Cited by
Applications of multi‐omics analysis in human diseases
Chen, C., Wang, J., Pan, D., Wang, X., Xu, Y., Yan, J., Wang, L., Yang, X., Yang, M., & Liu, G. (2023) · MedComm · doi:10.1002/mco2.315 · Cited by 545
MicroRNAs in Alzheimer’s Disease: Function and Potential Applications as Diagnostic Biomarkers
Wei, W., Wang, Z.-Y., Ma, L.-N., Zhang, T.-T., Cao, Y., & Li, H. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00160 · Cited by 103
Kodam, P., Sai Swaroop, R., Pradhan, S. S., Sivaramakrishnan, V., & Vadrevu, R. (2023) · Scientific Reports · doi:10.1038/s41598-023-30892-6 · Cited by 82
Qiu, Y., Hou, Y., Gohel, D., Zhou, Y., Xu, J., Bykova, M., Yang, Y., Leverenz, J. B., Pieper, A. A., Nussinov, R., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114128 · Cited by 40
“61 Another AD GWAS-supported orphan GPCR, GPR27, is highly expressed in human brain and is involved in neuronal plasticity and cognition 62–64 and has been shown to be elevated with cognitive decline.”
Using blood transcriptome analysis for Alzheimer's disease diagnosis and patient stratification
Zhong, H., Zhou, X., Uhm, H., Jiang, Y., Cao, H., Chen, Y., Mak, T. T. W., Lo, R. M. N., Wong, B. W. Y., Cheng, E. Y. L., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13691 · Cited by 25
Metadata
- Authors
- Peña-Bautista, C., Baquero, M., Vento, M., & Cháfer-Pericás, C.
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2019-06-19
- Volume
- 17
- Issue
- 7
- Pages
- 630-647
- ISSN
- 1570-159X (ISSN-L)
- OpenAlex
- W2892618895
- Cited by
- 35
- References
- 15
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.